Insulin Glargine versus Neutral Protamine Hagedorn Insulin for Treatment of Diabetes in Pregnancy

 

 Buy Article Permissions and Reprints

ABSTRACT

We compared maternal and neonatal outcomes in diabetic pregnancies treated with either insulin glargine or neutral protamine Hagedorn (NPH) insulin. We performed a retrospective chart review of diabetic pregnant patients using the Diabetes Care Center of Wake Forest University during the years 2000 to 2005. Outcomes of interest included maternal hemoglobin A1C, average fasting and 2-hour postprandial blood sugars, mode of delivery, birth weight, 5-minute Apgar score < 7, umbilical artery pH < 7.20, incidence of neonatal hypoglycemia, and pregnancy complications. A total of 52 diabetic pregnant patients were included in this study. Twenty-seven women used insulin glargine. A total of 13 women used insulin glargine during the first trimester. Glycemic control was similar in women who used NPH insulin and insulin glargine, as determined by hemoglobin A1C levels and mean blood sugar values. There were no differences in mode of delivery, average birth weight, or neonatal outcomes. Maternal and fetal/neonatal outcomes appear similar in pregnant diabetic women who use either NPH insulin or insulin glargine in combination with a short-acting insulin analogue to achieve adequate glycemic control during pregnancy. Insulin glargine appears to be an effective insulin analogue for use in women whose pregnancies are complicated by diabetes.

REFERENCES

• 1 Boney C M, Verma A, Tucker R, Vohr B R. Metabolic syndrome in childhood: association with birth weight, maternal obesity, and gestational diabetes mellitus.  Pediatrics. 2005;  115 e290-e296
  CrossrefPubMedGoogle Scholar
• 2 Silverman B L, Rizzo T A, Cho N H, Metzger B E. Long-term effects of intrauterine environment. The Northwestern University Diabetes in Pregnancy Center.  Diabetes Care. 1998;  21 B142-B149
  PubMedGoogle Scholar
• 3 Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.  Diabetes Care. 2005;  28 950-955
  CrossrefPubMedGoogle Scholar
• 4 Wang X L, Lu J M, Pan C Y et al.. Evaluation of the superiority of insulin glargine as basal insulin replacement by continuing glucose monitoring system.  Diabetes Res Clin Pract. 2007;  76 30-36
  CrossrefPubMedGoogle Scholar
• 5 Manini R, Forlani G, Moscatiello S, Zannoni C, Marzocchi R, Marchesini G. Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes.  Nutr Metab Cardiovasc Dis. 2007;  17 493-498
  CrossrefPubMedGoogle Scholar
• 6 Dolci M, Mori M, Baccetti F. Use of glargine insulin before and during pregnancy in a woman with type I diabetes and Addison's disease.  Diabetes Care. 2005;  28 2084-2085
  PubMedGoogle Scholar
• 7 Graves D E, White J C, Kirk J K. The use of insulin glargine with gestational diabetes mellitus.  Diabetes Care. 2006;  29 471-472
  PubMedGoogle Scholar
• 8 Woolderink J M, van Loon A J, Storms F, de Heide L, Hoogenberg K. Use of insulin glargine during pregnancy in seven type I diabetic women.  Diabetes Care. 2005;  28 2594-2595
  CrossrefPubMedGoogle Scholar
• 9 Di Cianni G, Volpe L, Lencioni C et al.. Use of insulin glargine during the first weeks of pregnancy in five type I diabetic women.  Diabetes Care. 2005;  28 982-983
  CrossrefPubMedGoogle Scholar
• 10 Holstein A, Plasche A, Egberts E H. Use of insulin glargine during embryogenesis in a pregnant woman with type I diabetes.  Diabet Med. 2003;  20 779-780
  CrossrefPubMedGoogle Scholar
• 11 Devlin J T, Hothersall L, Wilkis J L. Use of insulin glargine during pregnancy in a type I diabetic woman.  Diabetes Care. 2002;  25 1095-1096
  CrossrefPubMedGoogle Scholar
• 12 Torlone E, Gennarinia A, Ricci N B, Bolli G B. Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic women.  Eur J Obstet Gynecol Reprod Biol. 2007;  132 238-239
  CrossrefPubMedGoogle Scholar
• 13 Price N, Bartlett C, Gillmer M D. Use of insulin glargine during pregnancy: a case-control pilot study.  BJOG. 2007;  114 453-457
  PubMedGoogle Scholar
• 14 Gallen I W, Roland J M, Chirayath H H. Survey of glargine use in 115 pregnant women with type I diabetes.  Diabet Med. 2008;  25 165-169
  CrossrefPubMedGoogle Scholar
• 15 Hofmann T, Horstmann G, Stammberger I. Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits.  Int J Toxicol. 2002;  21 181-189
  CrossrefPubMedGoogle Scholar
• 16 Chatterjee S, Jarvis-Kay J, Rengarajan T, Lawrence I G, McNally P G, Davies M J. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes—the glargine and aspart study (GLASS) a randomised cross-over study.  Diabetes Res Clin Pract. 2007;  77 215-222
  CrossrefPubMedGoogle Scholar
• 17 Kurtzhals P, Schaffer L, Sorenson A et al.. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogues designed for clinical use.  Diabetes. 2000;  49 999-1005
  CrossrefPubMedGoogle Scholar
• 18 Ciaraldi T P, Carter L, Seipke G, Mudaliar S, Henry R R. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscles: comparisons to insulin and IGF-I.  J Clin Endocrinol Metab. 2001;  86 5838-5847
  CrossrefPubMedGoogle Scholar
• 19 Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Haring H U. The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp (B10) and regular insulin.  Horm Metab Res. 1998;  30 123-129
  Article in Thieme ConnectPubMedGoogle Scholar
• 20 Bähr M, Kolter T, Seipke G, Eckel J. Growth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31, ArgB32]insulin (HOE 901) in muscle cells.  Eur J Pharmacol. 1997;  320 259-265
  CrossrefPubMedGoogle Scholar
• 21 Stammberger I, Bube A, Durchfeld-Meyer B, Donaubauer H, Troschau G. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice.  Int J Toxicol. 2002;  21 171-179
  CrossrefPubMedGoogle Scholar
• 22 Lauszus F F, Klebe J G, Bek T, Flyvbjerg A. Increased serum IGF-1 during pregnancy is associated with progression of diabetic retinopathy.  Diabetes. 2003;  52 852-856
  CrossrefPubMedGoogle Scholar
• 23 Loukovarra S, Immonen I, Teramo K A, Kaaja R. Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro.  Diabetes Care. 2003;  26 1193-1198
  CrossrefPubMedGoogle Scholar
• 24 Kitzmiller J L, Main E, Ward B et al.. Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy.  , (Letter) Diabetes Care. 1999;  22 874-876
  CrossrefPubMedGoogle Scholar
• 25 Buchbinder A, Miodovnik M, McElvy S et al.. Is insulin lispro associated with the development or progression of diabetic retinopathy during pregnancy?.  Am J Obstet Gynecol. 2000;  183 1162-1165
  CrossrefPubMedGoogle Scholar
• 26 Garg S K, Frias J P, Anil S et al.. Insulin lispro therapy in pregnancies complicated by type I diabetes: glycemic control and maternal and fetal outcomes.  Endocr Pract. 2003;  9 187-193
  PubMedGoogle Scholar
• 27 Persson B, Swahn M L, Hjertberg R et al.. Insulin lispro therapy in pregnancies complicated by type-1 diabetes mellitus.  Diabetes Res Clin Pract. 2002;  58 115-121
  CrossrefPubMedGoogle Scholar

Jennifer G SmithM.D. Ph.D. 

Department of Obstetrics and Gynecology, Section on Maternal Fetal Medicine

Wake Forest University School of Medicine

Email: jgsmith@wfubmc.edu